MY ACCOUNT | NEWSLETTER |

New Research Offers Hope for Cats With Fibrosarcoma


Researchers at NC State’s College of Veterinary Medicine are mapping the genetic secrets behind fibrosarcoma, one of the most common cancers affecting cats. This work could transform how veterinarians diagnose and treat the disease.

Fibrosarcomas develop in a cat’s connective tissue and come in two main types. Injection-site sarcomas can appear months or even years after a vaccination or injection. They tend to grow aggressively and require extensive surgery. Non-injection-site fibrosarcomas are often less aggressive and easier to treat. The challenge? They look nearly identical under the microscope, making it difficult for veterinarians to determine the best treatment approach.

Drs. Matthew Breen and Rachael Thomas are identifying the specific genetic mutations that drive the tumors. By pinpointing which genes are altered in these cancers, they are uncovering new treatment targets and developing better ways to distinguish between the two types. This means more precise treatment plans and better outcomes for cats diagnosed with fibrosarcoma.

The research is funded by EveryCat Health Foundation through support from the Doris Day and Terry Melcher Foundation. The findings may also help other animals — and potentially humans — who develop similar tumors.


Source: https://news.cvm.ncsu.edu/

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Idiopathic Hypercalcemia in Cats

Like0
Dislike1

Unified Information Devices, Inc.

Like0
Dislike1

Effectiveness and long-term safety of repeated oral administrations of molidustat in the management of anemia associated with chronic kidney disease in cats.

Like0
Dislike1

The polysaccharide Pullulan improves the initial steps of allergen-specific immunotherapy in dogs.

Like0
Dislike1

Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study.

Like0
Dislike1

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top